IV HYOSICINE BUTYL BROMIDE WITH VAGINAL MISOPROSTOL FOR CERVICAL RIPENING

EFFICACY AND SAFETY OF COMBINING IV HYOSICINE BUTYL BROMIDE WITH VAGINAL MISOPROSTOL VERSUS VAGINAL MISOPROSTOL ALONE FOR CERVICAL RIPENING: A RANDOMISED CLINICAL TRIAL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201811685061976

Enrollment

Registered

2018-11-14

Start date

2019-09-30

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CERVICAL RIPENING

Interventions

IV hyoscine

PLACEBO

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: -Women booked for IOL -Singleton pregnancies

Exclusion criteria

Exclusion criteria: -Co-morbid medical illness -Multiple pregnancies -Allergies to hyoscine

Design outcomes

Primary

Measure	Time frame
The duration to achieve a favorable bishop score	—

Secondary

Measure	Time frame
Rates of caesarian and vaginal delivery, APGAR score at birth, maternal urinary output and side effects like nausea, dry mouth, maternal or fetal tachycardia.	—

Countries

Nigeria

Contacts

Public ContactSesan Oluwasola

Consultant Obs and Gyne

sesanoluwasola@yahoo.com08033384064

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026